American Journal of
Oral Medicine and Radiology

ISSN - 2394-7721

www.mcmed.us/journal/ajomr

Research Article

MYELODYSPLASIA SYNDROME CAUSED BY RADIOTHERAPY AND CHEMOTHERAPY

Lakshmi[1]* and Harsha Vardhan P[2]

[1]Associate Professor, Department of Obstetrics & Gynecology, Sree Balaji Medical College and Hospital, Chrompet, Chennai – 600044
[2]Assistant Professor, Department of Radiology, Tagore Medical College & Hospital, Chennai - 600127.

ABSTRACT
Myelodysplastic Syndrome (MDS) is a varied group closely related to clonal hematopoietic disorder characterized by hypocellular or hypercellular bone with morphology deformed and mature, as well as peripheral blood cytopenia, followed by progressive paralysis of the myelodysplastic stem cell -proclivity to evolve into acute myeloid leukemia (AML). This study is to evaluate Myelodysplasia Syndrome Caused by Radiotherapy and Chemotherapy. The adjusted odds ratio for MDS risk in non-CT patients was 1.51-fold (95 percent confidence interval: 1.25–1.82) greater than the odds ratio in CT patients. A substantial relationship between higher MDS risk and diabetes, stroke, and ischemic heart disease was found in patients who also used alkylating drugs or topoisomerase II inhibitors. Hematological malignancies have been linked to those who have been exposed to ionising radiation by accident, as well as cancer patients who have had radiation therapy. Alkylating medicines, topoisomerase II inhibitors, and antimetabolites, on the other hand, are often mentioned in the literature as causes of CT-induced MDS. Radiation treatment and chemotherapy are both linked to the later development of MDS, according to this population-based nested case–control study. Following cancer therapy, some tumour sites are more prone to the formation of MDS than others. It is possible that RT and CT have a beneficial relationship.

Key words:- Antimetabolites, CT patients , Diabetes.

Access this article online		
Home page: http://www.mcmed.us/journal/ajomr	Quick Response code	
Received:25.07.18	**Revised**:12.08.18	**Accepted**:14.09.18

INTRODUCTION

Our knowledge to date indicates that there has been no countrywide population-based investigation that has assessed treatment-related MDS for cancer in general or for specific individual malignancies. In India, we conducted research on this topic. It was our goal with this study to establish which initial cancer sites were more prone to the formation of MDS after therapy in cancer survivors, as well as to evaluate whether CT and RT interact. Since 1982, when it became the leading cause of death, cancer was ranked high. Since then, the inconsistency rate has grown steadily, rising in 2011 with 320.65 new cases per 100,000 people. [1] Effective cancer screening programs, early detection, improved diagnostic procedures, early and effective treatment, increased postoperative follow-up, and the aging population all contribute to an increase in those living with cancer for longer periods of time. [2] As a result, surveillance and monitoring of cancer survivors have become a major issue

Corresponding Author
Dr. Lakshmi

Email: -

regarding cancer management and cancer onset- and treatment-related health problems. [3]

Myelodysplastic syndrome (MDS) is a multidimensional group of closely related clonal hematopoietic disorders marked by hypocellular or hypercellular bone morphology deformed and mature, as well as peripheral blood cytopenias, followed by progressive paralysis of the myeodysplastic stem cell in acute myeloid leukemia (AML). [4,5,6] MDS appears to be associated with previous cancer treatment, whether chemotherapy (CT) or radiation (RT) (RT). MDS has been linked to cancer treatment for a variety of cancers, including breast cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, endometrial cancer, cervical cancer, prostate cancer, and brain cancer.

AIMS AND OBJECTIVES:

To evaluate the Myelodysplasia Syndrome Caused by Radiotherapy and Chemotherapy

Source of Information on Methods:

The National Health Insurance Research Database, was utilised in this retrospective nested case–control analysis. National Health Research Institutes creates and maintains LHID2000 data. In 2000, a random sample of 4.5 percent of people was randomly selected from the NHIRD claim site, and data on LHID2000 reflects that segment. There were no statistically significant differences in the distribution of sexual costs, age, or health care between groups at LHID2000 and general insurance subscribers, according to National Health Insurance Research Institute (NHRI). All personal information was kept completely confidential and secure as patient identification numbers and other personal information were encrypted.

Participants that were chosen at random

The exposure group was made up of those identified in the Registry for Catastrophic Illness Database who were 20 years of age or older and who had recently been diagnosed with primary cancer by ICD-9-CM 140-195 and 200-208 codes, without exception. myeloid leukemia (ICD-9-CM codes 205.0 and 205.10) between January 1, 2010, and December 31, 2015. Case registration in the Disaster Management Register, physician diagnosis, and confirmation reports of pathology or other supporting medical evidence. , required; these documents are then officially inspected by the insurance authorities. Patients with a history of MDS before 2000, as well as those with a history of MDS before a cancer diagnosis, were not included in the study. [11,12]

Patients in the case group were tracked until they were diagnosed with MDS (ICD-9-CM codes 284.9, 285.0, 205.10, and 205.0) in the years 2010-2015, while patients in the non-MDS group were followed up until diagnosed. via MDS. The diagnostic date was determined to be the MDS reference date. We randomly selected four people from the non-MDS group who were diagnosed with cancer at the same time as the case group and were usually associated with the case group by age (5 years), gender, age. of cancer diagnosis, and the MDS reference year to create a comparison group. [13,14] We included 1265 MDS patients as trial participants and 5057 non-MDS individuals as controls in this study.

MDS is associated with a number of potential comorbidities and treatments.

Diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code 272), stroke (ICD-9-CM codes 430–438), chronic obstructive pulmonary disease (ICD-9-CM codes 490–496), and alcoholism (ICD-9-CM codes 291, 303, 305.00, 305.01, 305.02, 305.03) were all considered comorbidities (ICD-9-CM codes 571.0, 571.1, and 571.3). [15,16]

We also looked at anti-cancer drugs, such as alkylating agents, topoisomerase II inhibitors, and antimetabolites, all of which have been linked to increased risk of MDS. [13] Prior to the reference date, two types of treatment, radiation and chemotherapy, were investigated for their possible association with MDS.

Examining the Data Statistical Analysis

In all subjects, a significant 0.05 rate was employed, using the SAS statistics software for Windows (version 9.3; SAS Institute, Inc., Cary, NC).

RESULTS:

Demographic data, baseline comorbidities, and treatment distributions are included in Table for comparison between the MDS and non-MDS populations. Women constituted 50.8 percent of the 1265 patients with MDS, and the majority of them were above the age of 65, according to the study (56.1 percent).[TABLE1] MDS groups and non-MDS groups were 65.2 years old (normal deviation: 14 14.8) and 65.2 (normal deviation: 14 14.8) years, respectively. Diabetes, stroke, ischemic heart disease, chronic obstructive pulmonary disease, alcoholism, the use of alkylating agents, the use of topoisomerase II inhibitor, and the use of antimetabolites were all more common in the MDS group than the non-MDS group. -MDS (all statistically significant; all P 0.05). The MDS group received significantly more RT and CT treatment than the non-MDS group, showing significant differences in treatment outcomes. The results of multivariable logistic regression models for the connection of RT and CT with MDS risk in cancer patients who had radiation and chemotherapy are shown in the table. Even after counting complications such as diabetes, stroke, ischemic heart disease, chronic obstructive pulmonary disease, alcoholism, and anti-cancer drugs, we found a 1.53-fold increase in MDS among cancer patients receiving treatment for RT compared to patients who did not receive it. RT treatment (95% confidence interval: 1.33–1.77). The adjusted odds ratio for MDS risk in non-CT patients was 1.51-fold (95 percent confidence interval:

1.25–1.82) greater than the odds ratio in CT patients. A substantial relationship between higher MDS risk and diabetes, stroke, and ischemic heart disease was found in patients who also used alkylating drugs or topoisomerase II inhibitors.

Table 1: Patient Demographic Details With Myeloplastic Syndrome

		MYELODYSPLASTIC SYNDROME		
	NO N=5057		**YES N=1265**	
	N	%	N	%
GENDER				
MEN	2573	50.9	643	50.8
WOMEN	2484	49.1	622	49.2
AGE				
20-49	880	17.4	220	17.4
50-64	1344	26.6	336	26.4
65-74	1283	25.4	321	25.4
>75	1550	30.6	388	30.4
MEAN	65.2	14.8	65.2	14.8
COMORBIDITIES				
DM	851	16.8	254	20.01
HTN	2515	49.8	652	21.5
HYPERLIPIDEMIA	1280	25.3	291	51.3
STROKE	394	7.77	130	10.02
IHD	1283	25.4	391	31
COPD	1977	39.1	550	43.5
ALCHOHOLISM	75	1.48	31	2.4

DISCUSSION:

This human-based case management study found that overall cancer treatment, whether radiation or chemotherapy, could significantly increase the chances of developing MDS in the future. According to the findings of the cancer study, patients with cancer of the stomach, colon, liver, breast, endometrial, prostate, and radiated kidneys were at higher risk of developing MDS. MDS has been shown to be more common in patients with lung cancer, endometrial cancer, and cervical cancer than in most people. Different patterns of MDS risk are seen in three different types of anti-cancer drugs between different tumors. Radiation therapy and computed tomography (CT) have a combined beneficial effect on the environment of MDS, according to further research. MDS is a common condition. About 20,000 cases of MDS were diagnosed in the United States in 2008, according to the National Cancer Institute, about 10 percent of those cases were linked to treatment. The French-American-British Cooperative Group has created a classification system based on laboratory data that is freely accessible for the first time. 16 The presence or absence of ring formed sideroblasts, antagonistic anemia (RAEBs), refractory anemia (RAEBs in transformation), and chronic myelomonocytic leukemia show up in each of the five categories. MDS has low prognosis, the majority of patients progressing to the AML antagonist within a few months after diagnosis.

Depending on the kind of cancer, a person's median survival period might range from months to years: [17] Therapeutic MDS is a rare but catastrophic long-term effect of cytotoxic drugs in primary diseases. As reported in the literature, traditional cancer treatment works by causing severe damage to the DNA, which limits cell growth and initiates cell death pathways. Because RT and CT do not only target cancer cells, they may also cause changes in healthy cells. When these cells live and contribute to the genes that control the proliferation and secretion of hemopoietic stem and precursor cells, aberrant myeloid cell clone may form (HSPCs). [13]

Hematological malignancies have been linked to those who have been exposed to ionising radiation by accident, as well as cancer patients who have had radiation therapy. [18–20] Alkylating medicines, topoisomerase II inhibitors, and antimetabolites, on the other hand, are often mentioned in the literature as causes of CT-induced MDS. [13,15] Alkylating agents are a type of anti-cancer drug that works in the treatment of almost all cancers, including lung cancer. 13 According to CDC, alkylating agents are the most common cause of treatment-related MDS. The condition was first diagnosed in Hodgkin's disease, but it has spread since then. The 15 MDS produced by topoisomerase II inhibitors usually detect quickly (within 1-3 years) and lead to moderate genetic mutations, as well as the 11q23 gene involved. most of the time. [21,22] Exposure to alkylating chemicals, on the other hand, causes the disease to appear later (between 5–10 years) and causes chromosomal imbalances, which often damage chromosomes 5 and 7. [23,24] Radiation-induced effects and chromosomal abnormalities are equal in magnitude

and severity to those reported after exposure to alkylating agents, according to a specific study. 25 Another class of cytostatic drugs, in addition to antimetabolites, has been linked to the development of therapeutic myeloid neoplasms. [13,26]

Conclusion

Radiation therapy and chemotherapy are both linked to the latest developments of the MDS, according to this human-based case management study. Following cancer treatment, some tumor sites are more prone to MDS formation than others. It is possible that RT and CT have a good working relationship. In order to confirm our findings, we will need to do more research. Physicians should evaluate the long-term risks of CT and RT, which include the development of chronic illness, according to research findings (MDS). However, this data is unquestionable with well-established benefits of RT and CT in cancer prevention, far outweighing the risk of MDS.

REFERENCES:

Cite this article:
Lakshmi and Harsha Vardhan P. Myelodysplasia Syndrome Caused by Radiotherapy And Chemotherapy. *American Journal of Oral Medicine and Radiology*, 2018, 5(2), 44-47.